These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

92 related articles for article (PubMed ID: 21893031)

  • 21. Immunological properties and vaccine efficacy of murine dendritic cells simultaneously expressing melanoma-associated antigen and interleukin-12.
    Okada N; Iiyama S; Okada Y; Mizuguchi H; Hayakawa T; Nakagawa S; Mayumi T; Fujita T; Yamamoto A
    Cancer Gene Ther; 2005 Jan; 12(1):72-83. PubMed ID: 15389286
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Adenoviral vectors targeted to CD40 enhance the efficacy of dendritic cell-based vaccination against human papillomavirus 16-induced tumor cells in a murine model.
    Tillman BW; Hayes TL; DeGruijl TD; Douglas JT; Curiel DT
    Cancer Res; 2000 Oct; 60(19):5456-63. PubMed ID: 11034088
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Interleukin 18 transfection enhances antitumor immunity induced by dendritic cell-tumor cell conjugates.
    Ju DW; Tao Q; Lou G; Bai M; He L; Yang Y; Cao X
    Cancer Res; 2001 May; 61(9):3735-40. PubMed ID: 11325846
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Murine dendritic cells pulsed with an anti-idiotype antibody induce antigen-specific protective antitumor immunity.
    Saha A; Chatterjee SK; Foon KA; Primus FJ; Bhattacharya-Chatterjee M
    Cancer Res; 2003 Jun; 63(11):2844-54. PubMed ID: 12782590
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [The mechanism of anti-tumor immune response against mouse melanoma to xenogeneic vaccination].
    Luo F; Mao YQ; Kan B; He QM; Jiang Y; Peng F; Yang L; Tian L
    Sichuan Da Xue Xue Bao Yi Xue Ban; 2004 Nov; 35(6):757-60. PubMed ID: 15573746
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Vaccines using dendritic cells, differentiated with propofol, enhance antitumor immunity in mice.
    Inada T; Kubo K; Shingu K
    Immunopharmacol Immunotoxicol; 2009; 31(1):150-7. PubMed ID: 19951075
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Comparison of recombinant adenovirus and synthetic peptide for DC-based melanoma vaccination.
    Steitz J; Tormo D; Schweichel D; Tüting T
    Cancer Gene Ther; 2006 Mar; 13(3):318-25. PubMed ID: 16151477
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Versatile prostate cancer treatment with inducible caspase and interleukin-12.
    Nikitina EY; Desai SA; Zhao X; Song W; Luo AZ; Gangula RD; Slawin KM; Spencer DM
    Cancer Res; 2005 May; 65(10):4309-19. PubMed ID: 15899823
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Strategies for antigen choice and priming of dendritic cells influence the polarization and efficacy of antitumor T-cell responses in dendritic cell-based cancer vaccination.
    Galea-Lauri J; Wells JW; Darling D; Harrison P; Farzaneh F
    Cancer Immunol Immunother; 2004 Nov; 53(11):963-77. PubMed ID: 15146294
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Combination vaccine of dendritic cells (DCs) and T cells effectively suppressed preestablished malignant melanoma in mice.
    Asada H; Kishida T; Hirai H; Shin-Ya M; Imanishi J; Takeuchi M; Mazda O
    Cancer Lett; 2006 Aug; 240(1):83-93. PubMed ID: 16246489
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Dendritic cells transduced with TAT protein transduction domain-containing tyrosinase-related protein 2 vaccinate against murine melanoma.
    Shibagaki N; Udey MC
    Eur J Immunol; 2003 Apr; 33(4):850-60. PubMed ID: 12672050
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Retrovirally transduced bone marrow-derived dendritic cells require CD4+ T cell help to elicit protective and therapeutic antitumor immunity.
    De Veerman M; Heirman C; Van Meirvenne S; Devos S; Corthals J; Moser M; Thielemans K
    J Immunol; 1999 Jan; 162(1):144-51. PubMed ID: 9886380
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Vaccine therapy of established tumors in the absence of autoimmunity.
    Hodge JW; Grosenbach DW; Aarts WM; Poole DJ; Schlom J
    Clin Cancer Res; 2003 May; 9(5):1837-49. PubMed ID: 12738742
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Mannan-modified adenovirus as a vaccine to induce antitumor immunity.
    Ding ZY; Wu Y; Luo Y; Su JM; Li Q; Zhang XW; Liu JY; He QM; Yang L; Tian L; Zhao X; Deng HX; Wen YJ; Li J; Kang B; Wei YQ
    Gene Ther; 2007 Apr; 14(8):657-63. PubMed ID: 17287861
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Depletion of CD25(+) CD4(+) T cells and treatment with tyrosinase-related protein 2-transduced dendritic cells enhance the interferon alpha-induced, CD8(+) T-cell-dependent immune defense of B16 melanoma.
    Steitz J; Brück J; Lenz J; Knop J; Tüting T
    Cancer Res; 2001 Dec; 61(24):8643-6. PubMed ID: 11751377
    [TBL] [Abstract][Full Text] [Related]  

  • 36. alpha-fetoprotein and interleukin-18 gene-modified dendritic cells effectively stimulate specific type-1 CD4- and CD8-mediated T-Cell response from hepatocellular carcinoma patients in Vitro.
    Cao DY; Yang JY; Dou KF; Ma LY; Teng ZH
    Hum Immunol; 2007 May; 68(5):334-41. PubMed ID: 17462500
    [TBL] [Abstract][Full Text] [Related]  

  • 37. In vivo splenic CD11c cells downregulate CD4 T-cell response thereby decreasing systemic immunity to gene-modified tumour cell vaccine.
    Cayeux S; Bukarica B; Buschow C; Charo J; Bunse M; Dörken B; Blankenstein T
    Gene Ther; 2007 Oct; 14(20):1481-91. PubMed ID: 17700709
    [TBL] [Abstract][Full Text] [Related]  

  • 38. A multi-trimeric fusion of CD40L and gp100 tumor antigen activates dendritic cells and enhances survival in a B16-F10 melanoma DNA vaccine model.
    Gupta S; Termini JM; Rivas Y; Otero M; Raffa FN; Bhat V; Farooq A; Stone GW
    Vaccine; 2015 Sep; 33(38):4798-806. PubMed ID: 26241951
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Targeting of antigens to activated dendritic cells in vivo cures metastatic melanoma in mice.
    Mahnke K; Qian Y; Fondel S; Brueck J; Becker C; Enk AH
    Cancer Res; 2005 Aug; 65(15):7007-12. PubMed ID: 16061687
    [TBL] [Abstract][Full Text] [Related]  

  • 40. CTL-dependent and -independent antitumor immunity is determined by the tumor not the vaccine.
    Leitch J; Fraser K; Lane C; Putzu K; Adema GJ; Zhang QJ; Jefferies WA; Bramson JL; Wan Y
    J Immunol; 2004 May; 172(9):5200-5. PubMed ID: 15100257
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.